Diagnosis and treatment of liver involvement secondary to rheumatic diseases

QUE Ziyuan, MENG Fanxing, LIU Chuntong, LIU Yanying, QI Haiyu

PDF(604 KB)
PDF(604 KB)
Journal of Clinical Hepatol ›› 2025, Vol. 41 ›› Issue (05) : 806-811. DOI: 10.12449/JCH250502
Expert Forum

Diagnosis and treatment of liver involvement secondary to rheumatic diseases

Author information +
History +

Abstract

Rheumatic diseases are chronic inflammatory autoimmune diseases that can affect multiple organs and systems. In clinical practice，most patients with rheumatic diseases present with asymptomatic liver function abnormalities during the course of the disease，and the etiology of such diseases may be associated with the rheumatic disease itself，medications，metabolism，viruses，or the presence of other chronic liver diseases. Immune-mediated inflammatory responses play a significant role in liver involvement （including hepatocyte injury，intrahepatic vascular lesions，and hepatic fibrosis） in rheumatic diseases. This article discusses the clinical features and management of liver involvement secondary to rheumatic diseases，in order to enhance the understanding of this condition among specialists in related fields.

Key words

Rheumatic Diseases / Liver Involvement / Diagnosis / Therapeutics

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
QUE Ziyuan , MENG Fanxing , LIU Chuntong , et al . Diagnosis and treatment of liver involvement secondary to rheumatic diseases. Journal of Clinical Hepatol. 2025, 41(05): 806-811 https://doi.org/10.12449/JCH250502

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
[1]
AFZAL W, HAGHI M, HASNI SA, et al. Lupus hepatitis, more than just elevated liver enzymes[J]. Scand J Rheumatol, 2020, 49(6): 427-433. DOI: 10.1080/03009742.2020.1744712.
本文引用 [3]
[2]
BESSONE F, POLES N, ROMA MG. Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis[J]. World J Hepatol, 2014, 6(6): 394-409. DOI: 10.4254/wjh.v6.i6.394.
本文引用 [1]
[3]
PIGA M, VACCA A, PORRU G, et al. Liver involvement in systemic lupus erythematosus: Incidence, clinical course and outcome of lupus hepatitis[J]. Clin Exp Rheumatol, 2010, 28(4): 504-510.
本文引用 [1]
[4]
ZHANG XY, ZHANG YX, WANG ZQ, et al. Study of 43 SLE patients with autoimmune liver cirrhosis: Emphasis on clinical features and differences from lupus without cirrhosis[J]. Int J Rheum Dis, 2023, 26(7): 1268-1275. DOI: 10.1111/1756-185X.14712.
本文引用 [1]
[5]
ADIGA A, NUGENT K. Lupus hepatitis and autoimmune hepatitis (lupoid hepatitis)[J].‍ Am J Med Sci, 2017, ‍353(4): 329-335. ‍DOI: ‍10.1016/j.amjms.2016.10.014.
本文引用 [2]
[6]
GEZER S. Antiphospholipid syndrome[J]. Dis Mon, 2003, 49(12): 696-741. DOI: 10.1016/j.disamonth.2003.10.001.
本文引用 [1]
[7]
TAGAWA Y, SAITO T, TAKADA K, et al. Successful treatment of severe refractory lupus hepatitis with mycophenolate mofetil[J]. Lupus, 2016, 25(5): 543-546. DOI: 10.1177/0961203315625118.
本文引用 [1]
[8]
FAN QY, JI HY, LIU Y, et al. Refractory lupus hepatitis successfully treated with telitacicept who failed to belimumab: A case report and literature review[J]. Lupus, 2024, 33(4): 414-419. DOI: 10.1177/09612033241233021.
本文引用 [1]
[9]
ARIAS-DE LA ROSA I, RUIZ-PONCE M, CUESTA-LÓPEZ L, et al. Clinical features and immune mechanisms directly linked to the altered liver function in patients with rheumatoid arthritis[J]. Eur J Intern Med, 2023, 118: 49-58. DOI: 10.1016/j.ejim.2023.08.002.
本文引用 [2]
[10]
ZHANG SP, ZHU P, YUAN JN, et al. Non-alcoholic fatty liver disease combined with rheumatoid arthritis exacerbates liver fibrosis by stimulating co-localization of PTRF and TLR4 in rats[J]. Front Pharmacol, 2023, 14: 1149665. DOI: 10.3389/fphar.2023.1149665.
本文引用 [1]
[11]
ATALLAH E, GROVE JI, CROOKS C, et al. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated[J]. J Hepatol, 2023, 78(5): 989-997. DOI: 10.1016/j.jhep.2022.12.034.
本文引用 [1]
[12]
EBERT EC, HAGSPIEL KD. Gastrointestinal and hepatic manifestations of rheumatoid arthritis[J]. Dig Dis Sci, 2011, 56(2): 295-302. DOI: 10.1007/s10620-010-1508-7.
本文引用 [1]
[13]
ZAMANI M, ALIZADEH-TABARI S, CHITKARA P, et al. Prevalence of nonalcoholic fatty liver disease in patients with rheumatoid arthritis: A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2023, 21(11): 2789-2796. DOI: 10.1016/j.cgh.2023.02.021.
本文引用 [1]
[14]
ORTOLAN A, LORENZIN M, TADIOTTO G, et al. Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients[J]. Clin Rheumatol, 2019, 38(10): 2843-2850. DOI: 10.1007/s10067-019-04646-7.
本文引用 [2]
[15]
VASSILOPOULOS A, KALLIGEROS M, VASSILOPOULOS S, et al. Prevalence of steatotic liver disease among US adults with rheumatoid arthritis[J]. Dig Dis Sci, 2024, 69(3): 989-1003. DOI: 10.1007/s10620-023-08225-4.
本文引用 [1]
[16]
RETAMOZO S, BALDINI C, BOOTSMA H, et al. Therapeutic recommendations for the management of older adult patients with Sjögren’s syndrome[J]. Drugs Aging, 2021, 38(4): 265-284. DOI: 10.1007/s40266-021-00838-6.
本文引用 [1]
[17]
MENG YH, CHEN YF, ZHOU PR. Clinical and immunological features of primary Sjögren’s syndrome patients with positive anti-centromere protein B antibody[J]. J Peking Univ (Health Sci), 2023, 55(6): 1088-1096. DOI: 10.19723/j.issn.1671-167X.2023.06.021.
孟彦宏, 陈怡帆, 周培茹. CENP-B抗体阳性的原发性干燥综合征患者的临床和免疫学特征[J]. 北京大学学报(医学版), 2023, 55(6): 1088-1096. DOI: 10.19723/j.issn.1671-167X.2023.06.021.
本文引用 [1]
[18]
LIU YX, GUO LX, LIN W, et al. Anticentromere antibody positive patients with primary Sjögren’s syndrome have distinctive clinical and immunological characteristics[J]. Clin Exp Rheumatol, 2023, 41(12): 2371-2378. DOI: 10.55563/clinexprheumatol/o3pxq0.
本文引用 [1]
[19]
ANDROUTSAKOS T, VOULGARIS TA, BAKASIS AD, et al. Liver fibrosis in primary Sjögren’s syndrome[J]. Front Immunol, 2022, 13: 889021. DOI: 10.3389/fimmu.2022.889021.
本文引用 [1]
[20]
ZHANG MJ, ZHANG S. T cells in fibrosis and fibrotic diseases[J]. Front Immunol, 2020, 11: 1142. DOI: 10.3389/fimmu.2020.01142.
本文引用 [1]
[21]
DENTON CP, KHANNA D. Systemic sclerosis[J]. Lancet, 2017, 390(10103): 1685-1699. DOI: 10.1016/s0140-6736(17)30933-9.
本文引用 [1]
[22]
UTIYAMA SR, ZENATTI KB, NÓBREGA HA, et al. Rheumatic disease autoantibodies in autoimmune liver diseases[J]. Immunol Invest, 2016, 45(6): 566-573. DOI: 10.1080/08820139.2016.1186173.
本文引用 [1]
[23]
SAWADPANICH K, PROMASEN P, MAIRIANG P, et al. Incidence and predictors of an abnormal liver function test among 674 systemic sclerosis patients: A cohort study[J]. Open Access Rheumatol, 2023, 15: 81-92. DOI: 10.2147/OARRR.S410165.
本文引用 [2]
[24]
LORENA M, BELLAN M, LEPORE M, et al. Clinical relevance of liver involvement in the clinical course of systemic sclerosis[J]. J Clin Med, 2022, 11(4): 966. DOI: 10.3390/jcm11040966.
本文引用 [1]
[25]
EBERT EC, HAGSPIEL KD, NAGAR M, et al. Gastrointestinal involvement in polyarteritis nodosa[J]. Clin Gastroenterol Hepatol, 2008, 6(9): 960-966. DOI: 10.1016/j.cgh.2008.04.004.
本文引用 [1]
[26]
SANSONNO D, DAMMACCO F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: Immune complex relations[J]. Lancet Infect Dis, 2005, 5(4): 227-236. DOI: 10.1016/S1473-3099(05)70053-0.
本文引用 [1]
[27]
ANDERSON E, GAKHAR N, STULL C, et al. Gastrointestinal and hepatic disease in vasculitis[J]. Rheum Dis Clin North Am, 2018, 44(1): 1-14. DOI: 10.1016/j.rdc.2017.09.001.
本文引用 [1]
[28]
UCHIDA T, FUKUI S, IWAMOTO N, et al. Absence of glucocorticoids concomitant with avacopan and subsequent liver injury in antineutrophil cytoplasmic antibody-associated vasculitis[J]. J Rheumatol, 2024, 51(11): 1146-1148. DOI: 10.3899/jrheum.2024-0340.
本文引用 [1]
[29]
MATHUR T, MANADAN AM, THIAGARAJAN S, et al. Serum transaminases are frequently elevated at time of diagnosis of idiopathic inflammatory myopathy and normalize with creatine kinase[J]. J Clin Rheumatol, 2014, 20(3): 130-132. DOI: 10.1097/RHU.0000000000000038.
本文引用 [1]
[30]
LANIS A, VOLOCHAYEV R, KLEINER DE, et al. Nodular regenerative hyperplasia of the liver in juvenile dermatomyositis[J]. Pediatr Rheumatol Online J, 2022, 20(1): 30. DOI: 10.1186/s12969-022-00690-x.
本文引用 [1]
[31]
NAGASHIMA T, KAMATA Y, IWAMOTO M, et al. Liver dysfunction in anti-melanoma differentiation-associated gene 5 antibody-positive patients with dermatomyositis[J]. Rheumatol Int, 2019, 39(5): 901-909. DOI: 10.1007/s00296-019-04255-2.
本文引用 [1]
[32]
YANG X, CUI XG, YANG X, et al. Liver involvement is associated with higher risk of rapidly progressive interstitial lung disease and mortality in anti-melanoma differentiation-associated gene 5 antibody- positive dermatomyositis[J]. J Inflamm Res, 2024, 17: 3101-3113. DOI: 10.2147/JIR.S462721.
本文引用 [1]
[33]
HOSOYA S, SADATSUKI M, IZUKA S, et al. A case of recurrence of adult-onset Still’s disease in the third trimester: A case report and literature review[J]. BMC Pregnancy Childbirth, 2021, 21(1): 163. DOI: 10.1186/s12884-021-03648-1.
本文引用 [2]
[34]
JIA JC, WANG MY, MENG JF, et al. Ferritin triggers neutrophil extracellular trap-mediated cytokine storm through Msr1 contributing to adult-onset Still’s disease pathogenesis[J]. Nat Commun, 2022, 13(1): 6804. DOI: 10.1038/s41467-022-34560-7.
本文引用 [1]
[35]
LI X, DONG CN, MA XW, et al. 18F-FDG PET/CT associates with disease activity and clinical recurrence of AOSD patients[J]. Front Med (Lausanne), 2021, 8: 668323. DOI: 10.3389/fmed.2021.668323.
本文引用 [1]
[36]
CHI HH, WANG ZH, MENG JF, et al. A cohort study of liver involvement in patients with adult-onset Still’s disease: Prevalence, characteristics and impact on prognosis[J]. Front Med (Lausanne), 2020, 7: 621005. DOI: 10.3389/fmed.2020.621005.
本文引用 [2]
[37]
MYLONA E, GOLFINOPOULOU S, SAMARKOS M, et al. Acute hepatitis in adult Still’s disease during corticosteroid treatment successfully treated with anakinra[J]. Clin Rheumatol, 2008, 27(5): 659-661. DOI: 10.1007/s10067-007-0791-y.
本文引用 [2]
[38]
MULLER R, BRIANTAIS A, FAUCHER B, et al. Acute severe hepatitis in adult-onset Still’s disease: Case report and comprehensive review of a life-threatening manifestation[J]. Clin Rheumatol, 2021, 40(6): 2467-2476. DOI: 10.1007/s10067-020-05383-y.
本文引用 [1]
[39]
TAYLOR SA, VITTORIO JM, MARTINEZ M, et al. Anakinra-induced acute liver failure in an adolescent patient with Still’s disease[J]. Pharmacotherapy, 2016, 36(1): e1-e4. DOI: 10.1002/phar.1677.
本文引用 [1]
[40]
TANAKA A, NOTOHARA K. Immunoglobulin G4(IgG4)-related autoimmune hepatitis and IgG4-hepatopathy: A histopathological and clinical perspective[J]. Hepatol Res, 2021, 51(8): 850-859. DOI: 10.1111/hepr.13683.
本文引用 [1]
[41]
LANZILLOTTA M, CULVER E, SHARMA A, et al. Fibrotic phenotype of IgG4-related disease[J]. Lancet Rheumatol, 2024, 6(7): e469-e480. DOI: 10.1016/S2665-9913(23)00299-0.
本文引用 [2]
[42]
BECQ A, CAMUS M, ARRIVÉ L, et al. IgG4-related sclerosing cholangitis presenting as an isolated intrahepatic stenosis: A rare presentation of a rare disease[J]. Endoscopy, 2021, 53(6): E205-E206. DOI: 10.1055/a-1244-9065.
本文引用 [2]
[43]
LIN H, LIU Y, WEI YY, et al. Characteristics of imaging in hepatic inflammatory pseudotumors: A comparison between IgG4-related and IgG4-unrelated cases[J]. Insights Imaging, 2024, 15(1): 203. DOI: 10.1186/s13244-024-01782-w.
本文引用 [2]
[44]
WANG TQ, LIU YY. Advances in diagnosis and treatment of IgG4-related hepatobiliary and pancreatic diseases[J]. J Clin Hepatol, 2022, 38(4): 762-766. DOI: 10.3969/j.issn.1001-5256.2022.04.006.
王天琪, 刘燕鹰. IgG4相关肝胆胰疾病诊疗进展[J]. 临床肝胆病杂志, 2022, 38(4): 762-766. DOI: 10.3969/j.issn.1001-5256.2022.04.006.
本文引用 [2]
[45]
LUO YP, PAN QQ, YANG HX, et al. Fibroblast activation protein-targeted PET/CT with 68Ga-FAPI for imaging IgG4-related disease: Comparison to 18F-FDG PET/CT[J]. J Nucl Med, 2021, 62(2): 266-271. DOI: 10.2967/jnumed.120.244723.
本文引用 [1]

阙子媛负责资料分析，撰写论文；孟繁星、刘春桐参与查阅文献，修改论文；齐海宇、刘燕鹰负责课题设计，拟定写作思路，指导撰写文章并最后定稿。

Funding

General Program of Beijing Natural Science Foundation(7222039)
General Program of Beijing Natural Science Foundation(7232029)

Comments

PDF(604 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Journal of Clinical Hepatol, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉